scholarly journals Del Nido cardioplegia is safe and effective myocardial protection in adult patients undergoing cardiac surgery: a single center experience

2019 ◽  
Author(s):  
Jakub Kuciński ◽  
Aleksandra Górska ◽  
Marek A. Deja
Keyword(s):  
Cardiac Surgery ◽  
Myocardial Protection ◽  
Adult Patients ◽  
Single Center ◽  
Single Center Experience

Single center experience with ECMO assist in 109 pediatric and adult patients with cardiac low-output syndrome

2007 ◽  
Vol 55 (S 1) ◽  
Author(s):  
P Brenner ◽  
S Daebritz ◽  
S Kainzinger ◽  
I Kaczmarek ◽  
R Sodian ◽  
...  
Keyword(s):  
Adult Patients ◽  
Single Center ◽  
Single Center Experience ◽  
Low Output Syndrome

Primary Malignant Sarcomas of the Heart and Great Vessels in Adult Patients — A Single‐Center Experience

2007 ◽  
Vol 12 (9) ◽  
pp. 1134-1142 ◽  
Author(s):  
Frank Mayer ◽  
Hermann Aebert ◽  
Maximilian Rudert ◽  
Alfred Königsrainer ◽  
Marius Horger ◽  
...  
Keyword(s):  
Adult Patients ◽  
Single Center ◽  
Single Center Experience ◽  
Great Vessels

MO291RITUXIMAB IS EFFECTIVE AND SAFE IN ADULTS WITH STEROID-DEPENDENT NEPHROTIC SYNDROME: A LONG-TERM, SINGLE-CENTER EXPERIENCE

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Gemma Patella ◽  
Alessandro Comi ◽  
Giuseppe Coppolino ◽  
Nicolino Comi ◽  
Giorgio Fuiano ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Case Series ◽  
Adult Patients ◽  
Single Center ◽  
Single Center Experience ◽  
Steroid Dependent ◽  
The Mean ◽  
Steroid Dependent Nephrotic Syndrome

Abstract Background and Aims Steroid-dependent nephrotic syndrome (SDNS) may require a prolonged multi-drug therapy with risk of drug toxicity and renal failure. Rituximab (RTX) treatment has been found to be helpful in reducing the steroid dosage and the need for immunosuppressants (ISs), but little data are currently available regarding very long-term outcomes in adults. We herein describe a long-term, single-center experience of RTX use in a large series of adults with SDNS. Method We studied 23 adult patients with SDNS (mean age 54.2±17.1 y; 65% male; BMI 28.5±4.7), mostly consequent to membranous (47.8%) or focal glomerulonephritis (30.2 %) who were eligible to start a RTX regimen. Before entering the RTX protocol, proteinuria and eGFR were 7.06±3.87 g/24h and 65.9±28.2 ml/min/1.73 m2, respectively; albumin and CD19/CD20 ratio were 2.9±0.9 g/L and 0.99±0.01 respectively; the mean number of ISs was 2.39±0.89 and the mean annual rate of relapses was 2.2±0.9. Results Patients were followed over a mean follow-up of 64 months (range: 12-144). After RTX (mean dose: 1202.1±372.4 mg) the rate of relapses was virtually nullified (p<0.001). eGFR remained roughly stable (62.1±19.8 ml/min/1.73 m2, p=NS), while proteinuria, albumin, CD19/CD20 and BMI all significantly improved (p ranging from 0.01 to 0.001). The mean number of additional ISs was also reduced (0.44±0.12; p<0.001) and RTX enabled discontinuation of steroids in 13/23 (56.5%) patients. No major adverse events related to therapy were recorded. Conclusion Findings from this large case-series with a remarkable very long follow-up reinforce the role of RTX as an efficient and safe weapon to improve outcomes in adult patients suffering from SDNS.

Sign in / Sign up

Export Citation Format

Share Document